Search Results

After doctoral training at the Pierre and Marie Curie University in Paris and a short internship at Genentech the CNRS as a Research Fellow in 1987 in the INSERM Laboratory directed by Jean-Charles Schwartz in Paris Neurobiology of Psychiatric Disorders," first in Créteil with Marion Leboyer, then at the University of Paris-Sorbonne

Brian Kobilka's lab at Stanford University and the SFMB laboratory at the Université Libre de Bruxelles

Developing new tools to uncover GPCR signaling patterns with Remi Janicot About Remi Janicot I was born in Paris

His laboratory is currently located at the Institute Cochin – Inserm (Paris, France).

Françoise Bachelerie " FB leads a team at Paris-Saclay University with expertise in immunology and virology

novel methods for systems biology using temporal logic specifications while pursuing his Ph.D. at INRIA Paris-Rocquencourt

Chieti in Italy, she completed her PhD in computational medicinal chemistry before spending a formative period

Receptor signaling assays showed efficacy shifts in the spinal cord and tolerance attenuation in the periaqueductal Brian Blagg's KU-32 actually promotes neuronal survival in diabetic peripheral neuropathy and is now

During my Scholar period I have published or contributed in 38 published scientific work mainly in the

He highlighted that he had to regain his confidence after a period of three failed experiments.

His early exposure to TRPV1 channels and peripheral pain mechanisms with Dr. “I started going through what I was going through… and that got me very interested in research.” — Alex

During this period David has made a significant contribution to the understanding of agonist/ antagonist

moving to Rockefeller University with a Howard Hughes Medical Institute appointment, Tom advanced a series coarse-grain sampling approaches for membrane proteins in collaborations with Thomas Huber , Xavier Periole

Following a post-doctoral period at Bristol Myers Squibb in Princeton USA, Andrew returned to the UK commercial products is Keltic Pharma Therapeutics Ltd , a biotechnology company co-founded by Andrew with series

Foord describes a period where his group repeatedly identified ligands for orphan receptors: the second

Please review this policy periodically.